Real‑World Insurance Access to FDA-Approved Ruxolitinib Cream in Vitiligo

Background: Vitiligo is a chronic autoimmune disease characterized by melanocyte loss and progressive skin depigmentation, resulting in substantial clinical and psychosocial burden. In July 2022, ruxolitinib cream became the first and only US Food and Drug Administration (FDA)–approved therapy for repigmentation of nonsegmental vitiligo. As utilization has increased since approval, understanding real-world insurance access has become increasingly important.Objectives: To characterize real‑world insurance approval outcomes for ruxolitinib cream among patients with vitiligo treated in routine US clinical practice, including temporal trends in utilization, rejection, and coverage across major US commercial health plans.Methods: A retrospective claims analysis was conducted using the Kythera Open Claims Database. Patients with ≥1 vitiligo diagnosis and ≥1 submitted ruxolitinib cream claim between July 19, 2022, and March 30, 2025, were included. Insurance approval outcomes were assessed overall, by calendar year, and across Medicaid, Medicare and major US commercial health plans. Analyses evaluated initial claim rejection, subsequent approval following rejection, and final approval status, as well as trends in claim volume and rejection rates over time.Results: A total of 44,006 patients met study criteria. Mean (SD) age was 44 (18.0) years, 50.8% were female, and 67.2% had no documented vitiligo-related treatment before their initial ruxolitinib cream claim. Overall, 67.4% of patients experienced no insurance rejection, and an additional 21.4% were initially rejected but subsequently approved, resulting in an overall approval rate of 88.8%. Among patients who were initially rejected and subsequently approved, median time to approval was 4 days (mean, 17.3 days). Approval rates were consistently high across major commercial insurers, including Aetna (86.0%), Anthem (87.5%), Blue Cross (88.1%), Cigna (88.9%), and UnitedHealthcare (89.6%). The number of patients submitting ruxolitinib cream claims increased steadily during the study period, while overall approval rates improved from 86.1% in 2022 to approximately 89%–90% in subsequent years.Conclusions: In this large real-world claims analysis, most patients with vitiligo ultimately had a paid claim for ruxolitinib cream, including many whose initial claim was rejected. Increasing utilization and paid claim rates over time suggest that access to ruxolitinib cream has improved following FDA approval. Overall, these findings suggest that most patients with vitiligo ultimately obtained insurance approval for ruxolitinib cream and may help inform clinician decision-making regarding treatment access.